Staff Reports
The Department of Labor has moved from talk to action and is finalizing a rule that will force pharmacy benefit managers — the shadowy middlemen in prescription-drug pricing — to disclose who pays them and how much. This final PBM fee‑disclosure rule, cleared through White House review, aims to force transparency on rebates, spread pricing and other payments that have been hidden from employers and plan fiduciaries for years.
What the final rule requires
The core of the new rule is simple: PBMs that serve ERISA‑covered, self‑insured group health plans must tell plan fiduciaries about all direct and indirect compensation they and certain affiliates receive. That means disclosures of rebates and manufacturer payments, fees from pharmacies (including affiliated pharmacies), and any spread pricing arrangements. The rule also gives fiduciaries audit and verification rights and requires PBMs to provide advance estimates and periodic reports of actual payments so employers can assess whether PBM fees are reasonable under ERISA.
Who it affects and why it matters
This hits the big players — think CVS Caremark, Express Scripts/Evernorth, Optum Rx/UnitedHealth — and the entire class of PBMs that manage prescription benefits for tens of millions of Americans. Why care? Because employers currently sign contracts with one hand and watch rebates and hidden fees flow through the system with the other. If employers can finally see the flows of money, they can renegotiate contracts, stop overpaying, and push back on pricing games that raise costs for workers and families.
Politics, pushback and likely court fights
The administration is selling this as keeping a campaign promise: Secretary Keith Sonderling has framed the move as “radical transparency” to expose drug‑cost middlemen, and President Donald Trump touts it as part of his effort to lower healthcare costs. Expect PBMs and industry trade groups to cry proprietary data and regulatory overreach and to mount legal challenges. Congress will keep poking the issue, too, but for once the shove is coming from the executive branch, not just Capitol Hill hearings.
Bottom line — follow the money
This is a big deal for employers and plan sponsors who want to control healthcare costs. The final Federal Register notice will spell out effective dates, definitions and compliance steps, so plan fiduciaries should read it closely as soon as it posts. Investors and PBMs will react, and some contracts will get renegotiated in the next selling season. For anyone tired of secret fees driving up drug prices, this rule offers daylight — and daylight tends to make bad deals pop like balloons.
